EC Number   |
Inhibitors |
Structure |
|---|
    2.7.1.91 | (1S)-1-(2-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol |
i.e. ZINC19691372 |
 |
| 2.7.1.91 | (1S,3R)-1-(3,4-dihydroxyphenyl)-2,3,4,9-tetrahydro-1H-b-carboline-3-carboxylic acid |
i.e. ZINC00095976 |
|
| 2.7.1.91 | (2R)-1-[5-methoxy-2-([[2-(methylsulfanyl)ethyl]amino]methyl)phenoxy]-3-(4-methylpiperazin-1-yl)propan-2-ol |
i.e. ZINC20254629 |
|
| 2.7.1.91 | (2R)-2-amino-4-(4-octylphenyl)butan-1-ol |
i.e. (R)-2-amino-4-(4-octylphenyl)butan-1-ol, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2 |
  |
| 2.7.1.91 | (2R,3S)-2-[[(4-octylphenyl)amino]methyl]pyrrolidin-3-ol |
inhibition of isoform Sk1 |
|
| 2.7.1.91 | (2R,3S)-3-amino-4-morpholin-4-yl-1-phenylbutan-2-ol |
i.e. (2R,3S)-3-amino-4-morpholino-1-phenylbutan-2-ol, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2 |
|
| 2.7.1.91 | (2R,3S,4E)-N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol |
potent, water-soluble, isoenzyme-specific inhibitor of SphK1. The inhibitor decreases growth and survival of human leukemia U937 and Jurkat cells, and enhances apoptosis and cleavage of Bcl-2. Lethality of SK1-I is reversed by caspase inhibitors and by expression of Bcl-2. The specific inhibitor of SphK1 warrants attention as potential addition to the therapeutic armamentarium in leukemia |
|
| 2.7.1.91 | (2R,3S,4E)-N-methyl-5-(4-pentylphenyl)-2-aminopent-4-ene-1,3-diol |
i.e. SK1-I, BML-258, isotype-specific SphK1 inhibitor. Treatment suppresses growth of LN229 and U373 glioblastoma cell lines and nonestablished human GBM6 cells. SK1-I also enhances glioblastoma multiforma cell death and inhibits their migration and invasion. Sk1-I enhances the survival of mice harboring LN229 intracranial tumors. SK1-I rapidly reduces phosphorylation of Akt but has no significant effect on activation of extracellular signal-regulated kinase 1/2 |
|
| 2.7.1.91 | (2R,3S,4E)-N-methyl-5-(4-pentylphenyl)-2-aminopent-4-ene-1,3-diol |
i.e. SK1-I, BML-258, isotype-specific SphK1 inhibitor. SK1-I markedly reduces the tumor growth rate of glioblastoma xenografts, inducing apoptosis and reducing tumor vascularization, and enhances the survival of mice harboring LN229 intracranial tumors |
|
| 2.7.1.91 | (2R,4S)-2-(hydroxymethyl)-1-[2-[4-([4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino)phenyl]ethyl]piperidin-4-ol |
- |
|
